Amyloid precursor protein secretase inhibitors - Pipeline Insight, 2024

This “Amyloid precursor protein secretase inhibitors - Pipeline Insight, 2024” report provides comprehensive insights about 5+ companies and 5+ pipeline drugs in Amyloid precursor protein secretase inhibitors pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

• Global coverage

Amyloid precursor protein secretase inhibitors Understanding

Amyloid precursor protein secretase inhibitors: Overview

According to the beta-amyloid (Abeta) hypothesis, compounds that inhibit gamma-secretase, the pivotal enzyme that generates Abeta, are potential therapeutics for Alzheimer's disease (AD). Studies in both transgenic and non-transgenic animal models of AD have indicated that gamma-secretase inhibitors, administered by the oral route, are able to lower brain Abeta concentrations. Inhibition of gamma-secretase presents a direct target for lowering Aß production in the brain as a therapy for Alzheimer's disease (AD).

Report Highlights

• The companies and academics are working to assess challenges and seek opportunities that could influence Amyloid precursor protein secretase inhibitors R&D. The therapies under development are focused on novel approaches for Amyloid precursor protein secretase inhibitors.

Amyloid precursor protein secretase inhibitors Emerging Drugs Chapters

This segment of the Amyloid precursor protein secretase inhibitors report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Amyloid precursor protein secretase inhibitors Emerging Drugs

Nirogacestat: SpringWorks TherapeuticsNirogacestat is an oral, selective, small molecule, gamma secretase inhibitor (GSI) in Phase 3 clinical development for patients with desmoid tumors. Gamma secretase is a protease complex that cleaves, or divides, multiple transmembrane protein complexes, including Notch, which, when dysregulated, can play a role in activating pathways that contribute to desmoid tumor growth.

It is currently in Phase III stage of development for the treatment of Desmoid tumors and is being developed by SpringWorks Therapeutics.

AL 101: Ayala PharmaceuticalsAL 101 is a novel, injectable, potent and selective small molecule gamma secretase inhibitor (GSI). The US Food and Drug Administration (FDA) granted Orphan Drug Designation and Fast Track Designation to AL101 for the potential treatment of Adenoid cystic carcinoma (ACC). It is currently in Phase II stage of development for the treatment of Amyloid precursor protein secretase inhibitors and is being developed by Ayala Pharmaceuticals.

Amyloid precursor protein secretase inhibitors: Therapeutic Assessment

This segment of the report provides insights about the different Amyloid precursor protein secretase inhibitors drugs segregated based on following parameters that define the scope of the report, such as:

Major Players working on Amyloid precursor protein secretase inhibitors

There are approx. 5+ key companies which are developing the Amyloid precursor protein secretase inhibitors. The companies which have their Amyloid precursor protein secretase inhibitors drug candidates in the most advanced stage, i.e. Phase III include, SpringWorks Therapeutics.

Phases

This report covers around 5+ products under different phases of clinical development like

• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage products (Phase I/II and Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

Route of Administration

Amyloid precursor protein secretase inhibitors pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Infusion
• Intradermal
• Intramuscular
• Intranasal
• Intravaginal
• Oral
• Parenteral
• Subcutaneous
• Topical

Molecule Type

Products have been categorized under various Molecule types such as

• Vaccines
• Monoclonal Antibody
• Peptides
• Polymer
• Small molecule

Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Amyloid precursor protein secretase inhibitors: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase III, II, I, preclinical and discovery stage. It also analyses Amyloid precursor protein secretase inhibitors therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Amyloid precursor protein secretase inhibitors drugs.

Amyloid precursor protein secretase inhibitors Report Insights

• Amyloid precursor protein secretase inhibitors Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Amyloid precursor protein secretase inhibitors Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions

Current Scenario and Emerging Therapies:

• How many companies are developing Amyloid precursor protein secretase inhibitors drugs?
• How many Amyloid precursor protein secretase inhibitors drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for Amyloid precursor protein secretase inhibitors?
• What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Amyloid precursor protein secretase inhibitors therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Amyloid precursor protein secretase inhibitors and their status?
• What are the key designations that have been granted to the emerging drugs?

Key Players

• Ayala Pharmaceuticals
• SpringWorks Therapeutics
• Pipeline Therapeutics

Key Products

• AL102
• AL 101
• Nirogacestat
• PIPE-505

This product will be delivered within 2 business days.